{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T05:30:38Z","timestamp":1770442238767,"version":"3.49.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.clinthera.2015.09.004","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T20:35:25Z","timestamp":1446669325000},"page":"2751-2769","source":"Crossref","is-referenced-by-count":27,"title":["Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct01252953","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01687998","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01749878","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01764633","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02107872","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02207634","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02265952","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02314442","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02472535","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Traci","family":"Turner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan A.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.09.004_bib1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.004_bib2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib3","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib4","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2015.09.004_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.004_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2015.10017","article-title":"New therapies in the treatment of high cholesterol: an argument to return to goal-based lipid guidelines","author":"Shrank","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.004_bib7","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib9","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib10","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.004_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib13","series-title":"Clinical Lipidology: A Companion to Braunwald\u05f3s Heart Disease","first-page":"346","article-title":"Evolving targets of therapy: proprotein convertase subtilisin\/kexin 9 inhibition","author":"Turner","year":"2014"},{"key":"10.1016\/j.clinthera.2015.09.004_bib14","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2015.09.004_bib15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-med-022613-090402","article-title":"Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9","volume":"65","author":"Stein","year":"2014","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib16","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2015.09.004_bib17","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib18","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","volume":"60","author":"Dias","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib19","unstructured":"European Commission Approves Amgen\u02bcs New Cholesterol-Lowering Medication Repatha\u2122 (evolocumab), the First PCSK9 Inhibitor To Be Approved in the World, for Treatment of High Cholesterol. http:\/\/www.amgen.com\/media\/media_pr_detail.jsp?releaseID=2069405&. Accessed 2015."},{"key":"10.1016\/j.clinthera.2015.09.004_bib20","unstructured":"FDA approves Praluent to treat certain patients with high cholesterol. http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm455883.htm. Accessed 2015."},{"key":"10.1016\/j.clinthera.2015.09.004_bib21","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","article-title":"Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia","volume":"115","author":"Ballantyne","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1208\/s12248-015-9750-8","article-title":"Modeling and simulation to support phase 2 dose selection for RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin\/kexin type 9","volume":"17","author":"Budha","year":"2015","journal-title":"Aaps J"},{"key":"10.1016\/j.clinthera.2015.09.004_bib23","doi-asserted-by":"crossref","first-page":"A1591","DOI":"10.1016\/S0735-1097(15)61591-1","volume":"65","author":"Kastelein","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib24","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib26","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib27","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2015.09.004_bib28","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.004_bib29","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.004_bib30","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib31","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib32","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled Phase III clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib34","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib35","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on ldl-c lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.004_bib36","series-title":"Presented at European Society of Cardiology Congress","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia (heFH) not adequately controlled with current lipid-lowering therapy: Results of ODYSSEY FH I and FH II studies","author":"Kastelein","year":"2014"},{"key":"10.1016\/j.clinthera.2015.09.004_bib37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies","volume":"28","author":"Kastelein","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.clinthera.2015.09.004_bib38","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib39","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9149(97)00298-1","article-title":"The rule of 5 and the rule of 7 in lipid-lowering by statin drugs","volume":"80","author":"Roberts","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib41","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib42","unstructured":"Moriarty PM. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm. Presented at AHA Scientific Sessions; 2014; Chicago, Ill."},{"key":"10.1016\/j.clinthera.2015.09.004_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib44","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.004_bib45","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib47","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1056\/NEJMc0707445","article-title":"Myocardial Infarction Genetics Consortium. A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib49","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2015.09.004_bib50","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia","volume":"29","author":"Cariou","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib51","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib52","unstructured":"Amgen Completes Enrollment in Large Cardiovascular Outcomes Trial of RepathaTM (Evolocumab) in Patients with High Cholesterol and Clinically Evident Cardiovascular Disease. http:\/\/www.prnewswire.com\/news-releases\/amgen-completes-enrollment-in-large-cardiovascular-outcomes-trial-of-repatha-evolocumab-in-patients-with-high-cholesterol-and-clinically-evident-cardiovascular-disease-300094614.html. Accessed 5, 2015."},{"key":"10.1016\/j.clinthera.2015.09.004_bib53","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2015.09.004_bib54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.114.214221","article-title":"Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering","volume":"350","author":"Mitchell","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2015.09.004_bib55","first-page":"63","article-title":"LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study","author":"Stein","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib56","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMra045004","article-title":"Therapeutic potential of RNA interference","volume":"351","author":"Stevenson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib58","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbic.201500023","article-title":"Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo","volume":"16","author":"Rajeev","year":"2015","journal-title":"Chembiochem"},{"key":"10.1016\/j.clinthera.2015.09.004_bib59","doi-asserted-by":"crossref","first-page":"e114469","DOI":"10.1371\/journal.pone.0114469","article-title":"Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management","volume":"9","author":"Galabova","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2015.09.004_bib60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib61","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40262-013-0071-8","article-title":"Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective","volume":"52","author":"Mohammadpour","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib62","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/CIRCULATIONAHA.114.014025","article-title":"Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP inhibition as a strategy to reduce cardiovascular risk: The Pro Case","volume":"132","author":"Barter","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.004_bib63","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/CIRCULATIONAHA.115.014026","article-title":"Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP as a target to lower CVD risk: suspension of disbelief?","volume":"132","author":"Hovingh","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.004_bib64","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib65","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib66","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ahj.2011.07.010","article-title":"Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia","volume":"162","author":"Dansky","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2015.09.004_bib67","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib68","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib69","unstructured":"Lilly Provides Update on Evacetrapib Phase 3 Trial https:\/\/investor.lilly.com\/releasedetail.cfm?ReleaseID=923885. Accessed 2015."},{"key":"10.1016\/j.clinthera.2015.09.004_bib70","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.004_bib71","unstructured":"Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension. http:\/\/investor.esperion.com\/releasedetail.cfm?ReleaseID=924113. Accessed 2015."},{"key":"10.1016\/j.clinthera.2015.09.004_bib72","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2015.09.004_bib73","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib74","doi-asserted-by":"crossref","first-page":"A1349","DOI":"10.1016\/S0735-1097(15)61349-3","article-title":"ETC-1002 lowers LDL-C more than ezetimibe in patients with hypercholesterolemia with or without statin intolerance and has a similar safety and tolerability profile","volume":"65","author":"Thompson","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib75","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.1994.03510330050033","article-title":"A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.004_bib76","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/archinte.1988.00380110121025","article-title":"EFfect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol\/high-density lipoprotein cholesterol ratio","volume":"148","author":"Luria","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2015.09.004_bib77","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.004_bib78","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project Patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib79","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mce.2015.01.029","article-title":"Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets","volume":"404","author":"Chen","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib80","doi-asserted-by":"crossref","first-page":"12027","DOI":"10.1073\/pnas.1534923100","article-title":"Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes","volume":"100","author":"Horton","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2015.09.004_bib81","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jacl.2015.03.100","article-title":"Phase 1 study of CAT-2054, an oral novel modulator of SREBP","volume":"9","author":"Donovan","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib82","unstructured":"Catabasis Pharmaceuticals Announces Positive Top-line Phase 1 Data for Hypercholesterolemia Product Candidate CAT-2054 [press release]. http:\/\/www.catabasis.com\/pdfs\/Catabasis-CAT-2054-101%20results%20final%2013august2015.pdf. Accessed 2015."},{"key":"10.1016\/j.clinthera.2015.09.004_bib83","doi-asserted-by":"crossref","first-page":"A9595","DOI":"10.1161\/circ.126.suppl_21.A9595","article-title":"A novel niacin analogue (ARI-3037MO) induces favorable plasma lipid changes without flush in single and multiple ascending dose placebo controlled trials in normal healthy volunteers","volume":"126","author":"Benedict","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.004_bib84","doi-asserted-by":"crossref","first-page":"549627","DOI":"10.1155\/2013\/549627","article-title":"Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases","volume":"2013","author":"Monsalve","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.clinthera.2015.09.004_bib85","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1210\/jc.2011-1061","article-title":"MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin","volume":"96","author":"Bays","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.09.004_bib86","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.atherosclerosis.2011.10.029","article-title":"Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia","volume":"220","author":"Choi","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2015.09.004_bib87","unstructured":"CymaBay Therapeutics Announces Preclinical Data Demonstrating the Potential of MBX-8025 to Treat Homozygous Familial Hypercholesterolemia [press release]. http:\/\/www.marketwatch.com\/story\/cymabay-therapeutics-announces-preclinical-data-demonstrating-the-potential-of-mbx-8025-to-treat-homozygous-familial-hypercholesterolemia-2015-01-28-8173233. Accessed 2015."},{"key":"10.1016\/j.clinthera.2015.09.004_bib88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0022-2275(20)34199-7","article-title":"A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor","volume":"39","author":"Bisgaier","year":"1998","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2015.09.004_bib89","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9149(03)00721-5","article-title":"Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol","volume":"92","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib90","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MOL.0b013e3283630cf0","article-title":"The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism","volume":"24","author":"Arca","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.clinthera.2015.09.004_bib91","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2015.09.004_bib92","unstructured":"Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3Rx [press release]. http:\/\/www.prnewswire.com\/news-releases\/isis-pharmaceuticals-reports-positive-phase-1-data-on-isis-angptl3-rx-300053962.html. Accessed 2015."},{"key":"10.1016\/j.clinthera.2015.09.004_bib93","unstructured":"Alnylam Pharmaceuticals. A Subcutaneous Platform for RNAi Therapeutics Targeting Metabolic Diseases: PCSK9 and ANGPTL3. Poster presented at AHA Scientific Sessions; 2014; Chicago, Ill."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815011029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815011029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T06:49:35Z","timestamp":1718174975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815011029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":93,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0149291815011029"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.09.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}